论文部分内容阅读
本文介绍单独应用基因重组型人类白细胞干扰素(rIFN-αA),治疗浆细胞肿瘤18例(多发性骨髓瘤16例,其中IgG 9例、B-J 型5例及IgA 2例;浆细胞白血病和巨球蛋白血症各1例),白血病3例(急淋2例、慢淋1例),恶性淋巴痛2例(非何杰金氏病和免疫母细胞性淋巴结病(IBL)各1例)共23例。男性15例,女性8例,年龄除1例急淋9岁外,余为21～77岁,中数年龄为58岁.首次用量,一般为3×10~(?)IU 肌肉注射,每三天递增,逐渐增为6×,9×,18×,36×,50×10~(?)IU.7例首次用量为6×10~(?)IU。3例白血病用200ml 生理盐水溶解后静点.
This article describes the separate application of recombinant human leukocyte interferon (rIFN-αA), treatment of plasma cell tumor in 18 cases (16 cases of multiple myeloma, including 9 cases of IgG, 5 cases of BJ type and IgA 2 cases; plasma cell leukemia and giant 1 case of leukemia, 2 cases of leukemia, 1 case of chronic lymphocytic leukemia, 2 cases of malignant lymphatic pain, 1 case of non-Hodgkin’s disease and 1 case of immunoblastic lymphadenopathy (IBL) A total of 23 cases. 15 males and 8 females, except for 1 case of acute lymphoblastic age 9 years old, the remaining 21 to 77 years old, the median age of 58. The first dose, usually 3 × 10 ~ (?) IU intramuscular injection, every three Day, and gradually increased to 6 ×, 9 ×, 18 ×, 36 ×, 50 × 10 ~ (?) IU, the first time the dosage of 6 × 10 ~ (?) IU. 3 cases of leukemia with 200ml saline dissolved after the static point.